You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 65 No. 12, December 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Alzheimer Disease
 •Neurogenetics
 •Radiologic Imaging
 •Magnetic Resonance Imaging
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Association of Distinct Variants in SORL1 With Cerebrovascular and Neurodegenerative Changes Related to Alzheimer Disease

Karen T. Cuenco, PhD; Kathryn L. Lunetta, PhD; Clinton T. Baldwin, PhD; Ann C. McKee, MD; Jianping Guo, MS; L. Adrienne Cupples, PhD; Robert C. Green, MD, MPH; Peter H. St. George-Hyslop, MD; Helena Chui, MD; Charles DeCarli, MD; Lindsay A. Farrer, PhD; for the MIRAGE Study Group

Arch Neurol. 2008;65(12):1640-1648.

Background  Single-nucleotide polymorphisms (SNPs) in 2 distinct regions of the gene for the sortilin-related receptor (SORL1) (bounded by consecutively numbered SNPs 8-10 and 22-25) were shown to be associated with Alzheimer disease (AD) in multiple ethnically diverse samples.

Objective  To test the hypothesis that SORL1 is associated with brain magnetic resonance imaging (MRI) measurements of atrophy and/or vascular disease.

Design, Setting, and Patients  We evaluated the association of 30 SNPs spanning SORL1 with MRI measures of general cerebral atrophy, hippocampal atrophy, white matter hyperintensities, and overall cerebrovascular disease in 44 African American and 182 white sibships from the MIRAGE Study. We performed single- and 3-SNP haplotype association analyses using family-based tests. Haplotypes found to be significantly associated with at least 1 MRI trait were tested for association with 6 pathological traits in a separate sample of 69 white patients with autopsy-confirmed AD.

Results  In white patients, white matter hyperintensities were associated with multiple markers in the region encompassing SNPs 6 to 10, whereas cerebral and hippocampal atrophy were associated with markers from the region including SNPs 21 to 26. Examination of specific 3-SNP haplotypes from these 2 regions in the autopsy-confirmed cases of AD revealed association of white matter disease with SNPs 8 to 10 and association of hippocampal atrophy with SNPs 22 to 26. The haplotype CGC at SNPs 8 to 10 was associated with fewer white matter changes in the clinical (P < .001) and autopsy (P = .02) samples.

Conclusions  Variants of SORL1 previously associated with AD are also associated with MRI and neuropathological measures of neurodegenerative and cerebrovascular disease. These findings not only support the hypothesis that multiple areas in SORL1 are of functional importance but also raise the possibility that multiple SORL1 variants influence amyloid precursor protein or endothelial lipoprotein processing or both in different regions of the brain.


Author Affiliations: Genetics Program, Department of Medicine (Drs T. Cuenco, Baldwin, Green, and Farrer and Ms Guo), Departments of Epidemiology (Drs T. Cuenco, Green, and Farrer), Biostatistics (Drs Lunetta, Cupples, and Farrer), Neurology (Drs McKee, Green, and Farrer), and Genetics and Genomics (Dr Farrer), and Center for Human Genetics (Dr Baldwin), Boston University Schools of Medicine and Public Health, Boston, Massachusetts; Centre for Research in Neurodegenerative Diseases, Department of Medicine, University of Toronto, Toronto, Ontario, Canada (Dr St. George-Hyslop); Cambridge Institute for Medical Research, Department of Clinical Neurosciences, University of Cambridge, Cambridge, England (Dr St. George-Hyslop); and Departments of Neurology, University of Southern California, Los Angeles (Dr Chui), and University of California, Davis, Sacramento (Dr DeCarli).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2008;65(12):1564-1565.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Implication of Sex and SORL1 Variants in Italian Patients With Alzheimer Disease
Cellini et al.
Arch Neurol 2009;66:1260-1266.
ABSTRACT | FULL TEXT  

Development of an Immunoassay for the Quantification of Soluble LR11, a Circulating Marker of Atherosclerosis
Matsuo et al.
Clin. Chem. 2009;55:1801-1808.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.